MedTrace Logo

Safety Study of Once-a-Day Dosing of Udenafil to Treat Erectile Dysfunction

NCT01901640 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 302

Last updated 2013-07-17

No results posted yet for this study

Summary

Phase : Phase III Indication : Erectile Dysfunction Study Design : open-label, fixed dose, 6-month extension study (parent study : DA8159\_EDD\_III)

Conditions

Interventions

DRUG

DA-8159 (Udenafil)

Sponsors & Collaborators

  • Dong-A Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • S W Kim, MD, PhD · the Catholic University of Korea St. Mary's Hospital

  • D G Moon, MD, PhD · Korea University Guro Hospital

  • J J Kim, MD, PhD · Korea University Anam Hospital

  • N C Park, MD, PhD · Pusan National University Hospital

  • S W Lee, MD, PhD · Samsung Medical Center

  • J S Paick, MD, PhD · Seoul National University Hospital

  • T Y Ahn, MD, PhD · Asan Medical Center

  • K H Moon, MD, PhD · Yeungnam University Hospital

  • W S Chung, MD, PhD · Ewha Womans University Hospital

  • K S Min, MD, PhD · Inje University

  • J K Park, MD, PhD · Chonbuk National University Hospital

  • D Y Yang, MD, PhD · Kangdong Sacred Heart Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2012-11-30
Completion
2012-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01901640 on ClinicalTrials.gov